Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 515-529

  Jabbour, Elias J ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCR ABL mutations; Molecular mechanisms; T315I

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; ALPHA INTERFERON; BAFETINIB; BOSUTINIB; DANUSERTIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PEGINTERFERON; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; XL 228;

ABNORMAL LABORATORY RESULT; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BCR ABL GENE; BRADYCARDIA; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; CYTOGENETICS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRY SKIN; DYSPNEA; EPIGENETICS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; GENE; GENE AMPLIFICATION; GENE DUPLICATION; GENETIC TRANSCRIPTION; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IC 50; INFECTION; LYMPHOCYTOPENIA; METABOLIC DISORDER; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

BCR-ABL MUTATIONS; MOLECULAR MECHANISMS; T315I;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84884137284     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.018     Document Type: Review

References (162)

1. A. Quintas-Cardama, H.M. Kantarjian, and J.E. Cortes Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia Cancer Control 16 2009 122 131
2. A. Hochhaus, S. Kreil, and A.S. Corbin Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2002 2190 2196
3. M.E. Gorre, M. Mohammed, and K. Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
4. P. le Coutre, E. Tassi, and M. Varella-Garcia Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766
5. ®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org/professionals/physician- gls/pdf/cml.pdf.
6. M. Baccarani, J. Cortes, and F. Pane Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
7. S. O'Brien, E. Berman, and J.O. Moore NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia J Natl Compr Canc Netw 9 Suppl 2 2011 S1 S25
8. E. Jabbour, H.M. Kantarjian, and S. O'Brien Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 29 2011 4260 4265
9. D. Marin, C. Hedgley, and R.E. Clark The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy Blood 118 Suppl 2011 Abstract No. 785
10. B. Hanfstein, M.C. Muller, and R. Hehlmann Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Leukemia 26 2012 2096 2102
11. G. Saglio, H.M. Kantarjian, and N. Shah Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data Blood 120 Suppl 2012 Abstract No. 1675
12. A. Hochhaus, T.P. Hughes, and G. Saglio Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials newly diagnosed patients) Blood 120 Suppl 2012 Abstract No. 167
13. D. Marin, A.R. Ibrahim, and C. Lucas Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors J Clin Oncol 30 2012 232 238
14. B.J. Druker, F. Guilhot, and S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
15. H. Kantarjian, C. Sawyers, and A. Hochhaus Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
16. S.G. O'Brien, F. Guilhot, and R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
17. Y. Alvarado, H. Kantarjian, and S. O'Brien Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase Cancer 115 2009 3709 3718
18. B. Peng, M. Hayes, and D. Resta Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 2004 935 942
19. R.A. Larson, B.J. Druker, and F. Guilhot Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 2008 4022 4028
20. S. Picard, K. Titier, and G. Etienne Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 2007 3496 3499
21. J.F. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1018 1029
22. C. Gambacorti-Passerini, M. Zucchetti, and D. Russo Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients Clin Cancer Res 9 2003 625 632
23. H.G. Jorgensen, M.A. Elliott, and E.K. Allan Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571 Blood 99 2002 713 715
24. F.X. Mahon, M.W. Deininger, and B. Schultheis Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079
25. J. Thomas, L. Wang, and R.E. Clark Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 2004 3739 3745
26. K. Skoglund, S. Boiso Moreno, and J.-I. Jönsson Functional characterization of ABCG2 polymorphisms and their influence on tyrosine kinase inhibitor effects in chronic myeloid leukemia cells Blood 118 2011 Abstract No. 3495
27. D.H. Kim, L. Sriharsha, and W. Xu Clinical relevance of a pharmacogenetic approach using multiple candidate gene polymorphisms to predict response and resistance to imatinib mesylate therapy in chronic myeloid leukemia Blood 110 2007 Abstract No. 737
28. L.C. Crossman, B.J. Druker, and M.W. Deininger hOCT 1 and resistance to imatinib Blood 106 2005 1133 1134
29. S. Galimberti, G. Cervetti, and F. Guerrini Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment Cancer Genet Cytogenet 162 2005 57 62
30. P.T. Ferrao, M.J. Frost, and S.P. Siah Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro Blood 102 2003 4499 4503
31. Y. Hu, S. Swerdlow, and T.M. Duffy Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice Proc Natl Acad Sci U S A 103 2006 16870 16875
32. S. Li, and D. Li Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors J Cell Mol Med 11 2007 1251 1262
33. S. Danhauser-Riedl, M. Warmuth, and B.J. Druker Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells Cancer Res 56 1996 3589 3596
34. N.J. Donato, J.Y. Wu, and J. Stapley BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 2003 690 698
35. J. Wu, F. Meng, and H. Lu Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood 111 2008 3821 3829
36. J. Sun, C.C. Yin, and W. Cui Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission Am J Clin Pathol 135 2011 391 397
37. T. Lahaye, B. Riehm, and U. Berger Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 2005 1659 1669
38. F.X. Gruber, T. Lundan, and R. Goll BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med Oncol 29 2012 219 226
39. J.E. Cortes, M. Talpaz, and F. Giles Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy Blood 101 2003 3794 3800
40. M.E. O'Dwyer, M.J. Mauro, and G. Kurilik The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML Blood 100 2002 1628 1633
41. C. Schoch, T. Haferlach, and W. Kern Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate Leukemia 17 2003 461 463
42. H.G. Wendel, E. de Stanchina, and E. Cepero Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proc Natl Acad Sci U S A 103 2006 7444 7449
43. D. Bixby, and M. Talpaz Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia Leukemia 25 2011 7 22
44. S.M. Lee, J.H. Bae, and M.J. Kim Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors J Pharmacol Exp Ther 322 2007 1084 1092
45. E. San José-Eneriz, X. Agirre, and A. Jimenez-Velasco Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia Eur J Cancer 45 2009 1877 1889
46. Y. Oki, H.M. Kantarjian, and V. Gharibyan Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 109 2007 899 906
47. J.P. Issa, V. Gharibyan, and J. Cortes Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 23 2005 3948 3956
48. P. Rousselot, F. Huguet, and D. Rea Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 2007 58 60
49. A.S. Corbin, A. Agarwal, and M. Loriaux Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity J Clin Invest 121 2011 396 409
50. S. Vaidya, K. Ghosh, and B.R. Vundinti Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review Eur J Haematol 87 2011 381 393
51. M. Copland, A. Hamilton, and L.J. Elrick Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 2006 4532 4539
52. H.G. Jorgensen, and T.L. Holyoake Characterization of cancer stem cells in chronic myeloid leukaemia Biochem Soc Trans 35 2007 1347 1351
53. A.S. Corbin, P. La Rosee, and E.P. Stoffregen Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 101 2003 4611 4614
54. P. La Rosee, and M.W. Deininger Resistance to imatinib: mutations and beyond Semin Hematol 47 2010 335 343
55. D.J. Barnes, D. Palaiologou, and E. Panousopoulou Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia Cancer Res 65 2005 8912 8919
56. D. Milojkovic, and J. Apperley Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia Clin Cancer Res 15 2009 7519 7527
57. T. O'Hare, C.A. Eide, and M.W. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2007 2242 2249
58. E. Jabbour, H. Kantarjian, and D. Jones Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 2006 1767 1773
59. T. Ernst, and A. Hochhaus Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression Semin Oncol 39 2012 58 66
60. S. Soverini, S. Colarossi, and A. Gnani Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. The GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 2006 7374 7379
61. S. Branford, J.V. Melo, and T.P. Hughes Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 2009 5426 5435
62. T. Ernst, P. Erben, and M.C. Muller Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica 93 2008 186 192
63. F. Guilhot, J. Apperley, and D.W. Kim Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood 109 2007 4143 4150
64. A. Hochhaus, H.M. Kantarjian, and M. Baccarani Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
65. J.S. Khorashad, H. de Lavallade, and J.F. Apperley Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression J Clin Oncol 26 2008 4806 4813
66. T.D. Kim, S. Turkmen, and M. Schwarz Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia Haematologica 95 2010 582 588
67. P. le Coutre, O.G. Ottmann, and F. Giles Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Blood 111 2008 1834 1839
68. S. Soverini, G. Martinelli, and G. Rosti ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia J Clin Oncol 23 2005 4100 4109
69. S. Soverini, A. Hochhaus, and F.E. Nicolini BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet Blood 118 2011 1208 1215
70. T. Schindler, W. Bornmann, and P. Pellicena Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
71. S. Branford, Z. Rudzki, and S. Walsh Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283
72. E. Weisberg, P.W. Manley, and W. Breitenstein Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
73. C. Tang, L. Schafranek, and D.B. Watkins Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways Leuk Lymphoma 52 2011 2139 2147
74. I.J. Griswold, M. MacPartlin, and T. Bumm Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Mol Cell Biol 26 2006 6082 6093
75. J. Cortes, E. Jabbour, and H. Kantarjian Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 2007 4005 4011
76. S. Soverini, A. Gnani, and S. Colarossi In early-chronic phase chronic myeloid leukemia patients treated with imatinib, resistance is rarely mediated by Abl kinase domain mutations Blood 110 2007 Abstract No. 1934
77. D.W. Kim, D. Kim, and S.H. Kim Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment Blood 116 2010 Abstract No. 3441
78. T. Hughes, M. Deininger, and A. Hochhaus Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
79. S. Branford Chronic myeloid leukemia: molecular monitoring in clinical practice Hematology Am Soc Hematol Educ Program 2007 376 383
80. N.P. Shah, J.M. Nicoll, and B. Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
81. A.S. Corbin, E. Buchdunger, and F. Pascal Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 J Biol Chem 277 2002 32214 32219
82. D.W. Sherbenou, M.J. Wong, and A. Humayun Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib Leukemia 21 2007 489 493
83. S. Chu, H. Xu, and N.P. Shah Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood 105 2005 2093 2098
84. D.W. Sherbenou, O. Hantschel, and I. Kaupe BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib Blood 116 2010 3278 3285
85. S.G. Willis, T. Lange, and S. Demehri High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2005 2128 2137
86. M. Azam, R.R. Latek, and G.Q. Daley Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 2003 831 843
87. M. Talpaz, N.P. Shah, and H. Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541
88. T. Terasawa, I. Dahabreh, and T.A. Trikalinos BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia PLoS Curr 2 2010 RRN1204
89. M. Alikian, G. Gerrard, and P.G. Subramanian BCR-ABL1 kinase domain mutations: methodology and clinical evaluation Am J Hematol 87 2012 298 304
90. D. Jones, S. Kamel-Reid, and D. Bahler Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology J Mol Diagn 11 2009 4 11
91. S. Branford, and T.P. Hughes Mutational analysis in chronic myeloid leukemia: when and what to do? Curr Opin Hematol 18 2011 111 116
92. T. Ernst, F.X. Gruber, and O. Pelz-Ackermann A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib Haematologica 94 2009 1227 1235
93. H.M. Kantarjian, J. Cortes, and F. Guilhot Diagnosis and management of chronic myeloid leukemia Cancer 109 2007 1365 1375
94. E. Morra, M. Michallet, and J. Steegmann Real-life rates of disease monitoring in clinical practice in Europe: the "unmet needs in CML and Ph+ALL" (UNIC) study Blood 118 2007 Abstract No. 1949
95. F. Giles Molecular monitoring of BCR-ABL transcripts - standardization needed to properly use, and further investigate the value of, a critical surrogate marker for success in therapy of chronic myeloid leukemia US Oncol Hematol 7 2011 138 142
96. L. Wang, K. Knight, and C. Lucas The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia Haematologica 91 2006 235 239
97. D.L. White, P. Dang, and J. Engler Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib J Clin Oncol 28 2010 2761 2767
98. S. Assouline, and J.H. Lipton Monitoring response and resistance to treatment in chronic myeloid leukemia Curr Oncol 18 2011 e71 e83
99. J. Cortes, A. Quintas-Cardama, and E. Jabbour The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk 11 2011 421 426
100. H.M. Kantarjian, R.A. Larson, and F. Guilhot Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase Cancer 115 2009 551 560
101. E. Jabbour, H.M. Kantarjian, and D. Jones Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy Blood 113 2009 2154 2160
102. J.A. Zonder, P. Pemberton, and H. Brandt The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment Clin Cancer Res 9 2003 2092 2097
103. M. Baccarani, G. Saglio, and J. Goldman Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820
104. M.W. Deininger, and T.L. Holyoake Can we afford to let sleeping dogs lie? Blood 105 2005 1840 1841
105. C. Preudhomme, J. Guilhot, and F.E. Nicolini Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2010 2511 2521
106. A. Burchert, M.C. Muller, and P. Kostrewa Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia J Clin Oncol 28 2010 1429 1435
107. A.M. Cornelison, M.A. Welch, C. Koller, and E. Jabbour Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation Clin Lymphoma Myeloma Leuk 11 Suppl 1 2011 S111 S113
108. F.E. Nicolini, S. Hayette, and L. Legros Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone Leuk Res 35 2011 80 86
109. H. Itonaga, H. Tsushima, and T. Hata Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa Int J Hematol 95 2012 209 213
110. T. O'Hare, D.K. Walters, and E.P. Stoffregen In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505
111. J.F. Apperley, J.E. Cortes, and D.W. Kim Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial J Clin Oncol 27 2009 3472 3479
112. H. Kantarjian, R. Pasquini, and V. Levy Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R) Cancer 115 2009 4136 4147
113. A. Hochhaus, M. Baccarani, and M. Deininger Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 2008 1200 1206
114. M.C. Muller, J.E. Cortes, and D.W. Kim Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations Blood 114 2009 4944 4953
115. S. Soverini, A. Gnani, and S. Colarossi Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Blood 114 2009 2168 2171
116. S. Soverini, S. Colarossi, and A. Gnani Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain Haematologica 92 2007 401 404
117. S. Soverini, G. Martinelli, and S. Colarossi Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL Lancet Oncol 8 2007 273 274
118. J.S. Khorashad, D. Milojkovic, and P. Mehta In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib Blood 111 2008 2378 2381
119. N.P. Shah, B.J. Skaggs, and S. Branford Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency J Clin Invest 117 2007 2562 2569
120. E. Weisberg, P. Manley, and J. Mestan AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 2006 1765 1769
121. H.M. Kantarjian, F. Giles, and N. Gattermann Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
122. H.M. Kantarjian, F.J. Giles, and K.N. Bhalla Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes Blood 114 2009 Abstract No. 1129
123. H. Kantarjian, F. Giles, and K. Bhalla Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study J Clin Oncol 27 Suppl 2009 Abstract No. 7029
124. F. Giles, P. le Coutre, and K. Bhalla A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib J Clin Oncol 25 Suppl 2007 Abstract No. 7038
125. H.A. Bradeen, C.A. Eide, and T. O'Hare Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood 108 2006 2332 2338
126. M. Puttini, A.M. Coluccia, and F. Boschelli In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells Cancer Res 66 2006 11314 11322
127. S. Redaelli, R. Piazza, and R. Rostagno Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants J Clin Oncol 27 2009 469 471
128. J.E. Cortes, H.M. Kantarjian, and T.H. Brummendorf Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Blood 118 2011 4567 4576
129. H.J. Khoury, C. Gambacorti-Passerini, and H.M. Kantarjian Bosutinib as therapy for chronic phase chronic myeloid leukemia following failure with imatinib plus dasatinib and/or nilotinib: 24-month minimum follow-up update Blood 120 2012 Abstract No. 3785
130. J.E. Cortes, H.M. Kantarjian, and D.-W. Kim Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 36-month minimum follow-up update Blood 120 2012 Abstract No. 3779
131. J.E. Cortes, H.M. Kantarjian, and N. Shah Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088
132. J.E. Cortes, D.-W. Kim, and J. Pinilla-Ibarz A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial Blood 120 2012 Abstract No. 163
133. H.M. Kantarjian, D.-W. Kim, and J. Pinilla-Ibarz Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL): 12-month follow-up of the PACE trial Blood 120 2012 Abstract No. 915
134. J. Cortes, R. Paquette, and M. Talpaz Preliminary clinical activity in a Phase I trial of the BCR-ABL/IGF- 1R/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation Blood 112 2008 Abstract No. 3232
135. H. Kantarjian, P. le Coutre, and J. Cortes Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance Cancer 116 2010 2665 2672
136. J. Cortes-Franco, H. Dombret, and P. Schafhausen Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia Blood 114 2009 Abstract No. 864
137. R.L. Paquette, N.P. Shah, and C.L. Sawyers PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL Blood 110 2007 Abstract No. 1030
138. J.M. Foran, F. Ravandi, and S. O'Brien Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia J Clin Oncol 26 Suppl 2008 Abstract No. 2518
139. J. Cortes, G.J. Roboz, and H.M. Kantarjian A Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML Blood 112 2008 Abstract No. 2967
140. J.E. Cortes, J.H. Lipton, and D. Rea Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation Blood 120 2012 2573 2580
141. J. Cortes-Franco, H.J. Khoury, and F.E. Nicolini Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter Phase 2/3 study Blood 114 2009 Abstract No. 644
142. J. Cortes-Franco, D. Raghunadharao, and P. Parikh Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter Phase 2/3 study Blood 114 2009 Abstract No. 861
143. M. Ayoubi, H.M. Kantarjian, and W. Wierda A Phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib Blood 114 2009 Abstract No. 2193
144. H.J. Khoury, J.E. Cortes, and H.M. Kantarjian Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure Blood 119 2012 3403 3412
145. H.M. Kantarjian, J.E. Cortes, and D.W. Kim Bosutinib safety profile and management of toxicities in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors Blood 118 2011 Abstract No. 2760
146. T. O'Hare, W.C. Shakespeare, and X. Zhu AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
147. Q. Yu, A.M. Eiring, and M.S. Zabriskie Partially or fully BCR-ABL independent mechanisms of in vitro resistance to ponatinib Blood 118 2011 Abstract No. 2481
148. N.P. Shah, C. Kasap, and R. Paquette Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228 Blood 110 2007 Abstract No. 474
149. S. Kimura, H. Naito, and H. Segawa NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 2005 3948 3954
150. A. Gontarewicz, and T.H. Brummendorf Danusertib (formerly PHA-739358)-a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor Recent Results Cancer Res 184 2010 199 214
151. M. Wetzler, and D. Segal Omacetaxine as an anticancer therapeutic: what is old is new again Curr Pharm Des 17 2011 59 64
152. A. Quintas-Cardama, H. Kantarjian, and J. Cortes Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 Cancer 115 2009 5382 5393
153. E.K. Allan, T.L. Holyoake, A.R. Craig, and H.G. Jorgensen Omacetaxine may
154. A. Quintas-Cardama, and J. Cortes Homoharringtonine for the treatment of chronic myelogenous leukemia Expert Opin Pharmacother 9 2008 1029 1037
155. F.E. Nicolini, J. Lipton, and H. Kantarjian Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs) J Clin Oncol 30 Suppl 2012 Abstract No. 6513
156. L.P. Akard, H. Kantarjian, and F.E. Nicolini Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs) J Clin Oncol 30 Suppl 2012 Abstract No. 6596
157. H.J. Khoury, J.E. Cortes, and M. Wetzler Blast phase chronic myeloid leukemia: a pooled analysis of subcutaneous omacetaxine mepesuccinate in treatment-resistant patients Blood 120 2012 Abstract No. 3753
158. M. Wetzler, H. Kantarjian, and F.E. Nicolini Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs) J Clin Oncol 30 Suppl 2012 Abstract No. 6604
159. A.J. Tipping, F.X. Mahon, and G. Zafirides Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs Leukemia 16 2002 2349 2357
160. M.M. Coude, O. Luycx, and M.E. Cariou Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation Br J Haematol 157 2012 407 410
161. P. Laneuville, C. Dilea, and O.Q. Yin Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia J Clin Oncol 28 2010 e169 e171
162. A. Oyekunle, E. Klyuchnikov, and S. Ocheni Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors Acta Haematol 126 2011 30 39